LabCorp

Velocity Clinical Research appoints Renata Berardocco as Executive Vice President and Managing Director for Latin America, aiming to expand its global network and leverage her experience in multisite networks and patient recruitment.

Global Immuno-Oncology Clinical Trials Market report analyzes current status, future trends, and growth, covering major players like ICON PLC, IQVIA Holdings Inc., Covance, BioNTech, and others. It provides historical, current, and forecast market size, segmentation, and regional analysis. Key factors influencing market dynamics, including drivers, restraints, and projections, are detailed. The report also offers insights into market shares, strategies, and emerging niche segments.

Veravas developed the VeraBIND Tau Assay, a blood test showing 92% agreement with tau PET imaging for Alzheimer's tau pathology, aiming to improve diagnostic accuracy and potentially delay disease onset.

Offshoring clinical trials market is rapidly expanding due to cost savings, quicker patient recruitment, and access to diverse populations, particularly in Asia-Pacific, Latin America, and Eastern Europe. Key factors driving growth include regulatory harmonisation, digital health tools, and remote monitoring. The market is projected to reach 12.4 billion USD by 2033, growing at a CAGR of 9.1%.

The Virtual Clinical Trials Market was valued at USD 8.78 billion in 2023 and is projected to reach USD 14.89 billion by 2032, growing at a CAGR of 6.07% from 2024 to 2032. The market is driven by digital innovations like AI-driven recruitment, data analytics, and telemedicine, enhancing trial efficiency and patient accessibility. Key companies include ICON, Parexel, IQVIA, and Medidata. North America leads in market share, while Europe is the fastest-growing region.

GENFIT updates on elafibranor progress, ACLF research, and upcoming milestones at The Liver Meeting® 2024.

Decentralized clinical trials use tech to enhance patient recruitment, retention, and engagement, reducing barriers. Labcorp's webinar on Dec 4, 2024, will discuss advanced logistics, micro-sampling tech, and the role of labs in decentralized trial designs.

The article discusses the challenges sponsors face with outsourced monitoring in clinical trials, emphasizing the need for stricter oversight and potential solutions, including reclaiming in-house monitoring to ensure patient safety and data integrity.

An 80-something patient with normal cognitive tests for 10 years received a positive Alzheimer’s biomarker test, causing panic. The test indicates increased risk, not an early stage of the disease. The medical community’s urgency to classify positive biomarkers as “Stage One Alzheimer’s” is potentially harmful, causing unnecessary stress. Biomarker tests should only be considered if there are noticeable cognitive symptoms, and lifestyle changes can improve cognitive function. Widespread testing should be avoided until better predictive tools and treatments are available.

FDA approves Caris Life Sciences' MI Cancer Seek as companion diagnostic for multiple cancer drugs across six cancer types, including solid tumours, breast cancer, colorectal cancer, melanoma, non-small cell lung cancer, and endometrial carcinoma. The assay uses whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for molecular profiling of solid tumours.